AI Insight
Researchers have identified a potential vulnerability in glioblastoma by targeting the protein SET, which when blocked, prevented tumor formation in preclinical models. The approach works by restoring the activity of PP2A, a tumor-suppressing enzyme that glioblastoma cells typically inhibit. Additionally, targeting related proteins increased the cancer cells' susceptibility to radiation therapy.
Why it matters
Glioblastoma is one of the most aggressive and treatment-resistant brain cancers, with limited effective therapies currently available. This discovery could lead to new combination treatment strategies that make these deadly tumors more vulnerable to existing therapies like radiation.
Understand the Science
Researchers may have found a new way to weaken glioblastoma’s defenses against treatment. Blocking a protein called SET prevented tumors from forming in preclinical models, while targeting related proteins made cancer cells more vulnerable to radiation. The strategy works by restoring activity of PP2A, an enzyme that glioblastoma cells appear to suppress. Human testing will be needed to determine whether the approach is safe and effective.
Source: Scientists find a weak spot in one of the deadliest brain cancers